Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

European Journal of Cancer

Volumn 82, Issue , 2017, Pages 171-183

  Ives, Natalie J ^a   Suciu, Stefan ^b,h   Eggermont, Alexander M M ^c,h   Kirkwood, John ^d,h   Lorigan, Paul ^e,h   Markovic, Svetomir N ^f,h   Garbe, Claus ^g,h   Wheatley, Keith ^a,h   Bufalino, Rosaria ^h   Cameron, David ^h   Cascinelli, Natale ^h   Doherty, Valerie ^h   Gore, Martin ^h   Hancock, Barry ^h   Harrison, Rebecca ^h   Ives, Natalie ^h   Kressig, Michael ^h   Lee, Sandra ^h   MacKie, Rona ^h   Marsden, Jerry ^h   Suman, Vera ^h   Turner, Lesley ^h   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f MAYO CLINIC ROCHESTER   (United States)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h NONE

Author keywords

Adjuvant interferon; Individual patient data meta analysis; Melanoma; Randomised controlled trials

Indexed keywords

ALPHA INTERFERON; VACCINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; EVENT FREE SURVIVAL; HUMAN; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NEOPLASMS; SURVIVAL ANALYSIS; ULCER;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SURVIVAL ANALYSIS; ULCER;

EID: 85021715890     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.06.006     Document Type: Review

References (29)

1. Lens, M.B., Dawes, M., Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20 (2002), 1818–1825.
2. Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., Blum, R.H., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996), 7–17.
3. Kirkwood, J.M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M.S., Rao, U., Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10 (2004), 1670–1677.
4. Kirkwood, J.M., Ibrahim, J.G., Sondak, V.K., Richards, J., Flaherty, L.E., Ernstoff, M.S., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 (2000), 2444–2458.
5. Grob, J.J., Dreno, B., de la Salmoniere, P., Delaunay, M., Cupissol, D., Guillot, B., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351 (1998), 1905–1910.
6. Eggermont, A.M., Suciu, S., Santinami, M., Testori, A., Kruit, W.H., Marsden, J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008), 117–126.
7. Wheatley, K., Ives, N.J., Hancock, B., Gore, M., Eggermont, A., Suciu, S., Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003), 241–252.
8. Wheatley, K., Ives, N., Eggermont, A., Kirkwood, J., Cascinelli, N., Markovic, S.N., et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol, 25(Suppl), 2007 [Abstract 8526].
9. Mocellin, S., Lens, M.B., Pasquali, S., Pilati, P., Chiarion Sileni, V., Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev, 6, 2013 Jun 18, 10.1002/14651858.CD008955.pub2 CD008955.
10. Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
11. Stewart, L.A., Clarke, M.J., Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 14 (1995), 2057–2079.
12. Early Breast Cancer Trialists’ Collaborative Group, Treatment of early breast cancer. Vol. 1: worldwide evidence 1985–1990. 1990, Oxford University Press, Oxford.
13. Parmar, M.K., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998), 2815–2834.
14. Stewart, L.A., Clarke, M., Rovers, M., Riley, R.D., Simmonds, M., Stewart, G., et al., PRISMA-IPD Development Group. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 313 (2015), 1657–1665.
15. Eggermont, A.M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., et al., EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005), 1189–1196.
16. Creagan, E.T., Dalton, R.J., Ahmann, D.L., Jung, S.H., Morton, R.F., Langdon, R.M. Jr., et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13 (1995), 2776–2783.
17. McMasters, K.M., Ross, M.I., Reintgen, D.S., Edwards, M.J., Noyes, R.D., Urist, M., et al. Final results of the Sunbelt melanoma trial. J Clin Oncol, 26(Suppl), 2008 [Abstract 9003].
18. Hansson, J., Aamdal, S., Bastholt, L., Brandberg, Y., Hernberg, M., Nilsson, B., et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 12 (2011), 144–152.
19. Cascinelli, N., Belli, F., MacKie, R.M., Santinami, M., Bufalino, R., Morabito, A., Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358 (2001), 866–869.
20. Hancock, B.W., Wheatley, K., Harris, S., Ives, N., Harrison, G., Horsman, J.M., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22 (2004), 53–61.
21. Garbe, C., Radny, P., Linse, R., Dummer, R., Gutzmer, R., Ulrich, J., et al. Adjuvant low-dose interferon alpha-2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19 (2008), 1195–1201.
22. Pehamberger, H., Soyer, H.P., Steiner, A., Kofler, R., Binder, M., Mischer, P., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16 (1998), 1425–1429.
23. Cameron, D.A., Cornbleet, M.C., MacKie, R.M., Hunter, J.A., Gore, M., Hancock, B., et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish Study. Br J Cancer 84 (2001), 1146–1149.
24. Kleeberg, U.R., Suciu, S., Brocker, E.B., Ruiter, D.J., Chartier, C., Lienard, D., et al., EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40 (2004), 390–402.
25. Kirkwood, J.M., Ibrahim, J.G., Sosman, J.A., Sondak, V.K., Agarwala, S.S., Ernstoff, M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001), 2370–2380.
26. Kirkwood, J.M., Ibrahim, J., Lawson, D.H., Atkins, M.B., Agarwala, S.S., Collins, K., et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19 (2001), 1430–1436.
27. Eggermont, A.M., Suciu, S., Testori, A., Kruit, W.H., Marsden, J., Punt, C.J., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48 (2012), 218–225.
28. Eggermont, A.M., Spatz, A., Robert, C., Cutaneous melanoma. Lancet 383 (2014), 816–827.
29. Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.